1
by Ho, Chuong, Lau, Andrea, Cimon, Karen, Farrah, Kelly
Published 2012
Canadian Agency for Drugs and Technologies in Health
...), and other gram-negative bacteria may produce the enzymes known as extended spectrum beta-lactamases (ESBL...

2
by Banerjee, Srabani, McCormack, Suzanne
Published 2020
Canadian Agency for Drugs and Technologies in Health
...., fentanyl), propofol, and ketamine. Ketamine is a N-methyl-D aspartate receptor antagonist that produces a...

3
by Banerjee, Srabani, McCormack, Suzanne
Published 2020
Canadian Agency for Drugs and Technologies in Health
...., fentanyl), propofol, and ketamine. Ketamine is a N-methyl-D aspartate receptor antagonist that produces a...

4
Published 2017
Canadian Agency for Drugs and Technologies in Health
... of pain severe enough to require daily, continuous, long-term opioid treatment. Buprenorphine produces...

5
Published 2015
Canadian Agency for Drugs and Technologies in Health
... alone. The finding of this report can help produce clinical evidence as well as policy directions...

6
by Pohar, Ron, Farrah, Kelly
Published 2019
Canadian Agency for Drugs and Technologies in Health
... tissue, and the time required to produce a written pathology reports. The potentially low diagnostic...

7
Published 2012
Canadian Agency for Drugs and Technologies in Health

8
Published 2015
Canadian Agency for Drugs and Technologies in Health
... alone. The finding of this report can help produce clinical evidence as well as policy directions...

9
by Pohar, Ron, Farrah, Kelly
Published 2019
Canadian Agency for Drugs and Technologies in Health
... tissue, and the time required to produce a written pathology reports. The potentially low diagnostic...

10
Published 2012
Canadian Agency for Drugs and Technologies in Health

11
Published 2014
Canadian Agency for Drugs and Technologies in Health
... produce adverse events and they also have a slower onset of action, during which there may be an increase...

14
Published 2014
Canadian Agency for Drugs and Technologies in Health
... produce adverse events and they also have a slower onset of action, during which there may be an increase...

15
Published 2018
Canadian Agency for Drugs and Technologies in Health

16
by Janoudi, Ghayath, McCormack, Suzanne
Published 2020
Canadian Agency for Drugs and Technologies in Health
... in the survival motor neuron protein. A second set of genes, SMN2, is able to produce small amounts of the SMN...

17
Published 2014
Canadian Agency for Drugs and Technologies in Health
... cyclooxygenase (COX) enzymes that are needed to produce prostaglandin. Ketorolac tromethamine (Toradol) is a...

18
Published 2018
Canadian Agency for Drugs and Technologies in Health

19
Published 2014
Canadian Agency for Drugs and Technologies in Health
...Electroconvulsive therapy (ECT) is a treatment that uses a small electrical current to produce a...

20
Published 2014
Canadian Agency for Drugs and Technologies in Health
...Electroconvulsive therapy (ECT) is a treatment that uses a small electrical current to produce a...